You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Dow
Boehringer Ingelheim
Merck
Mallinckrodt

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 7,811,562

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,811,562
Title:Biomarkers for pre-selection of patients for anti-IGF1R therapy
Abstract: The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.
Inventor(s): Wang; Yan (Scotch Plains, NJ), Pachter; Jonathan A. (Setauket, NY), Wang; Yaolin (Edison, NJ), Liu; Ming (Fanwood, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:11/290,687
Patent Claims:see list of patent claims

Details for Patent 7,811,562

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Schering Corporation (Kenilworth, NJ) 2024-12-03 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Schering Corporation (Kenilworth, NJ) 2024-12-03 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Schering Corporation (Kenilworth, NJ) 2024-12-03 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Boehringer Ingelheim
Mallinckrodt
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.